DGX Related Analyst Ratings
-
Goldman Sachs Upgrades Laboratory Corporation of America (LH) to Neutral
-
Goldman Sachs Upgrades Quest Diagnostics (DGX) to Buy
-
UPDATE: Oppenheimer Starts Quest Diagnostics (DGX) at Underperform on Restructuring Risk and Bearish Industry Dynamics
-
Credit Suisse Downgrades Quest Diagnostics (DGX) to Neutral
-
WallachBeth Capital Starts Quest Diagnostics (DGX) at Hold
-
LabCorp (LH) Could See a Hit from Aetna/Coventry Health Deal
-
RBC Capital Downgrades Quest Diagnostics (DGX) to Sector Perform
-
Canaccord Genuity Q2 Preview on Quest Diagnostics (NYSE: DGX): Sidelined Until More Confident in New CEO's Ability
-
Canaccord Genuity Maintains a 'Buy' on Laboratory Corporation (LH); Q2 Preview: Successful Commercial Lab Business
-
Goldman Sachs Upgrades Quest Diagnostics (DGX) to Neutral
-
Canaccord Genuity Starts Quest Diagnostics (DGX) at Hold; Long-Term Outlook Promising, But Lacking N-T Catalysts
-
Raymond James Downgrades Quest Diagnostics (DGX) Two Notches to Underperform
-
Auriga Reiteratess a 'Hold' on Laboratory Corporation (LH); Expect In-line to Slightly Better 4Q Results
-
Jefferies Raises Price Target On Quest Diagnostics (DGX) to $66
-
Auriga Reiterates a 'Hold' on Quest Diagnostics (DGX); 4Q11: A Solid Quarter with Cost Management Highlighted
-
Macquarie Downgrades Quest Diagnostics (DGX) to Neutral
-
Auriga Starts Quest Diagnostics (DGX) at Hold
-
Barclays on Health Care Facilities: Perspectives on Medicare Reimbursement for Molecular Diagnostic Testing
-
Mizuho Securities Starts Quest Diagnostics (DGX) at Neutral
-
RBC Capital Upgrades Quest Diagnostics (DGX) to Outperform
-
UBS Maintains a 'Neutral' on Quest Diagnostics (DGX); Prospects for EPS Growth Brighten
-
Standpoint Cuts Quest Diagnostics (DGX) to Hold
-
Susquehanna Starts Quest Diagnostics (DGX) at Neutral
-
Maxim Group Downgrades Quest Diagnostics (DGX) to Hold
-
Raymond James Downgrades Quest Diagnostics (DGX) to Market Perform
-
Natixis Bleichroeder Starts Quest Diagnostics (DGX) at Buy
-
Goldman Sachs Downgrades Quest Diagnostics (DGX) to Sell
-
UBS Maintains a 'Neutral' on Quest Diagnostics (DGX); Smoke in the Air for the Lab Industry
-
Goldman Sachs Upgrades Quest Diagnostics (DGX) to Neutral
-
Standpoint Research Upgrades Quest Diagnostics (DGX) to Buy
-
Jefferies Downgrades Quest Diagnostics (DGX) to Hold
-
Barclays Maintains an 'Overweight' on Laboratory Corp of America (LH); Medi-Cal Settlement a Non-Event
-
RBC Capital Downgrades Quest Diagnostics (DGX) to Sector Perform
-
JPMorgan Starts Quest Diagnostics (DGX) at Neutral
-
Barclays Maintains an 'Overweight' on Quest Diagnostics (DGX); March Quarter Review: Top 3 Questions
-
Kaufman Bros. Raises Price Target on Quest Diagnostics (DGX) Due to Improving Volumes
-
UBS on U.S. Healthcare Distribution - Labs: Q1 Clinical Lab Quarterly Preview
-
Raymond James Starts Quest Diagnostics (DGX) at Outperform
-
Macquarie Starts Quest Diagnostics (DGX) at Outperform
-
UPDATE: Credit Suisse Raises Price Target on Quest (DGX), Volume Trends Look Positive for 2011
-
Quest Diagnostics (DGX) Added to Focus List at Credit Suisse
-
Credit Suisse Upgrades Quest Diagnostics (DGX) to Outperform
-
Barclays Maintains an 'Overweight' on Quest Diagnostics (DGX); 2010 10-K Review
-
Barclays maintains an 'Overweight' on Quest Diagnostics (DGX); Perspectives on Celera: Time Will Tell
-
Caris & Co. Starts Quest Diagnostics (DGX) at Average
-
Collins Stewart Starts MEDNEX (MD), DaVita (DVA), Lab Corp. (LH), Fresenius (FMS) at Buy, Quest (DGX) at Hold
-
Barclays Maintains an 'Overweight' on Quest Diagnostics (DGX); Perspectives on Share Repurchase and Guidance Increase
-
Kaufman Bros. Ups Estimates and PT on Quest Diagnostics (DGX) After Share Buyback News
-
Quest Diagnostics (DGX) Shares Up Modestly Following Morgan Stanley Upgrade
-
Morgan Stanley Upgrades Quest Diagnostics (DGX) to Equalweight
Back to DGX Stock Lookup
